Arcellx (ACLX) Return on Capital Employed (2022 - 2025)
Arcellx (ACLX) recorded quarterly Return on Capital Employed of 9.14% in Q4 2025, up 119.56% quarter-over-quarter from 46.72% in Q3 2025, and up 3159.0% on a YoY basis from 0.28% in Q4 2024.
Arcellx (ACLX) Return on Capital Employed (2022 - 2025) Analysis & Trends
Arcellx's Return on Capital Employed history runs 4 years deep, the most recent figure standing at 9.14% for Q4 2025.
- In Q4 2025, Return on Capital Employed rose 3159.0% year-over-year to 9.14%; the TTM figure through Dec 2025 stood at 9.14% (up 3159.0% YoY), while the FY2025 annual figure was 8.68%, up 3008.0% from the prior year.
- Return on Capital Employed was 9.14% for Q4 2025 at Arcellx, up from 46.72% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 9.14% in Q4 2025 to a low of 71.13% in Q4 2022.
- Historically, Return on Capital Employed has averaged 33.06% across 4 years, with a median of 33.38% in 2025.
- The sharpest annual moves came in 2023 and 2025: Return on Capital Employed jumped 5619 bps in 2023, then sank 3539 bps in 2025.
- A 4-year view of Return on Capital Employed shows it stood at 71.13% in 2022, then soared by 79 bps to 14.94% in 2023, then slumped by 50 bps to 22.45% in 2024, then jumped by 141 bps to 9.14% in 2025.
- The last three Return on Capital Employed figures came in at 9.14% (Q4 2025), 46.72% (Q3 2025), and 41.9% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 9.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.14% |
| Sep 30, 2025 | -46.72% |
| Jun 30, 2025 | -41.90% |
| Mar 31, 2025 | -33.61% |
| Dec 31, 2024 | -22.45% |
| Sep 30, 2024 | -11.33% |
| Jun 30, 2024 | -12.06% |
| Mar 31, 2024 | -10.83% |
| Dec 31, 2023 | -14.94% |
| Sep 30, 2023 | -32.51% |
| Jun 30, 2023 | -41.51% |
| Mar 31, 2023 | -64.71% |
| Dec 31, 2022 | -71.13% |
| Sep 30, 2022 | -55.25% |
| Jun 30, 2022 | -33.16% |
| Mar 31, 2022 | -46.02% |